Neogen's stock takes a hit as analysts lower price targets, despite insider buying.

Neogen's stock has faced a downgrade with Guggenheim lowering its price target to $10.00 but maintaining a "buy" rating, while Piper Sandler dropped its target to $5.00 and rated it "neutral." Despite a negative net margin of 53.56% in the latest quarter, Neogen, which specializes in genomics-based diagnostics, has seen insiders buy 83,500 shares recently. The average 12-month price target is now $8.62, down 27.26% from $11.85, reflecting market and performance shifts.